Shizhen Capital
时真资本
Shizhen Capital (时真资本, also referred to as New Day Fund) is a venture capital firm that appears in elsewhere's corpus primarily as a participant in the August 2025 $131 million pre-IPO round for Minghui Pharmaceutical, co-led by OrbiMed and Qiming Venture Partners, alongside investors including 5Y Capital and Boyuan Capital . The bundle does not contain foundational details about the firm itself—such as its founding year, fund size, team, or investment strategy—beyond this single deal appearance.
AI-generated — may contain errors, please verify.
Coverage
5Y News｜Minghui Pharma Closes $131 Million Pre-IPO Round to Accelerate Pipeline Development and Global Expansion
Dedicated to developing innovative therapies that address unmet clinical needs worldwide.
Minghui Pharmaceutical Raises $131M in Pre-IPO Round Co-Led by Qiming Venture Partners
Minghui Pharmaceutical is a late-stage biopharmaceutical company focused on oncology and autoimmune diseases.
